Summary. Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. Objectives: To establish a common international consensus addressing practical, clinically relevant questions in this setting. Methods: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system. Results: For the initial treatment of established VTE: low-molecular-weight heparin (LMWH) is recommended [1B]; fondaparinux and unfractionated heparin (UFH) can be also used [2D] ; thrombolysis may only be considered on a case-bycase basis [Best clinical practice (Guidance)]; vena cava filters (VCF) may be considered if contraindication to anticoagulation or pulmonary embolism recurrence under optimal anticoagu-lation; periodic reassessment of contraindications to anticoagulation is recommended and anticoagulation should be resumed when safe; VCF are not recommended for primary VTE prophylaxis in cancer patients [Guidance] . For the early maintenance (10 days to 3 months) and long-term (beyond 3 months) treatment of established VTE, LMWH for a minimum of 3 months is preferred over vitamin K antagonists (VKA) [1A]; idraparinux is not recommended [2C] ; after 3-6 months, LMWH or VKA continuation should be based on individual evaluation of the benefit-risk ratio, tolerability, patient preference and cancer activity [Guidance] . For the treatment of VTE recurrence in cancer patients under anticoagulation, three options can be considered: (i) switch from VKA to LMWH when treated with VKA; (ii) increase in LMWH dose when treated with LMWH, and (iii) VCF insertion [Guidance] . For the prophylaxis of postoperative VTE in surgical cancer patients, use of LMWH o.d. or low dose of UFH t.i.d. is recommended; pharmacological prophylaxis should be started 12-2 h preoperatively and continued for at least 7-10 days; there are no data allowing conclusion that one type of LMWH is superior to another [1A] ; there is no evidence to support fondaparinux as an alternative to LMWH [2C]; use of the highest prophylactic dose of LMWH is recommended [1A] ; extended prophylaxis (4 weeks) after major laparotomy may be indicated in cancer patients with a high risk of VTE and low risk of bleeding [2B] ; the use of LMWH for VTE prevention in cancer patients undergoing laparoscopic surgery may be recommended as for laparotomy [Guidance] ; mechanical methods are not recommended as monotherapy except when pharmacological methods are contraindicated [2C] . For the prophylaxis of VTE in hospitalized medical patients with cancer and reduced mobility, we recommend prophylaxis with LMWH, UFH or fondaparinux [1B] ; for children and adults with acute lymphocytic leukemia treated with L-asparaginase, depending on local policy and patient characteristics, prophylaxis may be considered in some patients [Guidance] ; in patients receiving chemotherapy, prophylaxis is not recommended routinely [1B]; primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic pancreatic [1B] or lung [2B] cancer treated with chemotherapy and having a low risk of bleeding; in patients treated with thalidomide or lenalidomide combined with steroids and/or chemotherapy, VTE prophylaxis is recommended; in this setting, VKA at low or therapeutic doses, LMWH at prophylactic doses and low-dose aspirin have shown similar effects; however, the efficacy of these regimens remains unclear [2C] . Special situations include brain tumors, severe renal failure (CrCl < 30 mL min )1
Introduction
Cancer is an independent and major risk factor for venous thromboembolism (VTE) [1, 2] . VTE, defined as deep-vein thrombosis (DVT) or pulmonary embolism (PE), is reported in up to 20% of patients with cancer [3] . Although the association between cancer and thrombosis has been known since TrousseauÕs first report [4] , cancer care providers now have increased awareness of the impact of thrombotic complications in their patients. Several factors have contributed to this heightened awareness. First, cancer-associated VTE is increasingly prevalent. In an analysis of more than one million hospitalized patients with cancer, the rate of VTE increased by 28% from 1995 to 2003 (P < 0.0001) [5] . Second, the consequences of VTE are better understood. Thrombosis is the second leading cause of death in patients with cancer [6] . Furthermore, VTE is an independent prognostic factor of mortality in cancer patients. Cancer patients with VTE have a shorter overall survival than cancer patients without VTE at the same tumor stage and receiving the same anti-cancer treatment [1, 3] . In addition, patients with cancer who also suffer from VTE have an increased risk of recurrent VTE, bleeding complications, morbidity, and utilization of health care resources [7, 8] .
Therefore, the prevention and treatment of VTE in cancer patients represent major challenges in daily practice. As cancer patients often present with a variety of risk factors and comorbidities, specific oncology guidelines on the subject have been established using various methodological approaches. Several national and international guidelines for the prevention and treatment of VTE in cancer patients have been published in the past [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Their methodological quality varies widely. In addition, underuse of VTE prophylaxis represents a major problem in daily life, and use of adequate prophylaxis is even less frequent among cancer patients [19] . In view of these issues, an international multidisciplinary working group was set up, following the initiative of the ÔGroupe Francophone Thrombose et CancerÕ (GFTC), with the collaboration of the Academic Medical Centre (AMC) and the University Medical Center Groningen (UMCG), the Netherlands, to develop harmonized guidelines for cancer patients, using the GRADE system, an up-to-date evidencebased clinical practice guideline development approach, with the methodological support of the French Institute of Cancer (INCa). In this article, we present the results and conclusions of this working group on the prevention and treatment of VTE in cancer patients.
Methods

Working group
The working group comprised 24 experts from various specialties (oncology, hematology, internal medicine, vascular medicine, biology and epidemiology), including two methodologists (PD and MB) and two coordinators (DF and HRB), as well as one nurse.
Literature review and analysis
We searched MEDLINE Ò and several other databases (e.g. EMBASE, CCTR, etc.), including national guidelines and several evidence-based medicine sites (Table S1 of Supporting Information), for articles published in French or English between January 1996 and January 2011. This literature search was prospectively continued up to June 2011. The search terms were cancer, venous thromboembolism (VTE), anticoagulant drugs, unfractionated heparin, low-molecular-weight heparin and treatments, and therefore included vitamin K antagonists, new oral anticoagulants and external compression devices. Panelists who had participated in previous guideline working groups or who were authors of meta-analyses supplied further references not retrieved by the literature search, as well as data previously extracted [10] [11] [12] 20] .
We included in the analysis, meta-analyses, systematic reviews, randomized clinical trials, or non-randomized prospective or retrospective studies in the absence of randomized clinical trials, but excluded editorials, letters to the editor, case reports, publications without an abstract, press releases and animal studies. Abstracts were included only if the data had subsequently been presented in full in an article published in a peer-reviewed medical journal. If no specific studies in patients with cancer could be retrieved, we included in the analysis studies performed in the general population of VTE patients, but including patients with cancer. In this case, the results were extrapolated to cancer patients and methodological biases were taken into account.
For inclusion in the analysis, studies had to focus on the therapeutic management of confirmed VTE in cancer patients (including initial treatment, early maintenance and long-term treatment of established VTE, as well as treatment to prevent VTE recurrence) or the prophylaxis of VTE in cancer patients in the surgical and medical settings. Studies in patients with catheter-related thrombosis will be reported separately. Studies in patients with thrombosis related to tumor material or a history of cancer in remission for more than 5 years were excluded from the analysis. Studies which did not include as outcomes VTE or side-effects of anticoagulation were also excluded.
The main study outcomes were rates of VTE (first event or recurrence), major and minor bleeding, thrombocytopenia and death. Major bleeding was defined as fatal bleeding, bleeding into a critical organ, or clinically overt bleeding associated with a decrease in hemoglobin level of more than 2 g dL )1 or leading to the transfusion of two or more units of blood [21, 22] . Minor bleeding was defined as all other bleeds.
Critical appraisal and data extraction
The quality of the studies was evaluated in a double-blind manner by the two methodologists (PD and MB) using validated critical appraisal (methodology and clinical relevance) and data extraction grids. Discrepancies in opinion between the two methodologists were resolved by discussion and, in the event of persisting disagreement, by a third expert (DF). Data were then extracted and entered in evidence tables, which were subsequently validated by all the working group members.
Consensus development
For each question, the results of the literature analysis were summarized and discussed by the whole working group taking into account the critical appraisal and data extraction grids.
Overall conclusions with the corresponding levels of evidence were formulated on the basis of the pooled results and conclusions for each question and the degree of agreement between the studies, using the GRADE system [23, 24] . The level of evidence (Table 1) depended on the study design as well as on study limitations, inconsistency, indirectness, imprecision and publication bias [23, 24] . Recommendations were established based on these assessments and the corresponding levels of evidence, as well as the balance between desirable and undesirable effects, values and preferences, and costs. They were classified as ÔStrongÕ (Grade 1 Guideline) or ÔWeakÕ (Grade 2 Guideline) based on the degree of confidence that the desirable effects of adherence to a recommendation outweigh the undesirable effects (Table 2) [23, 24] . In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international experts within the working group and defined as ÔBest Clinical PracticeÕ (Guidance).
The Guidelines were then peer-reviewed in February 2012 by 42 independent experts worldwide encompassing all medical and surgical specialties involved in the management of patients with cancer, and by three volunteer patient representatives selected from each panelistÕs patient population or from the patient associations with which the panelists were in contact. The peer review was performed according to a grid allowing quantitative and qualitative appraisal of the draft Guidelines. This process enabled us to consider both practionersÕ and 
Results
Treatment of established VTE
Several retrospective [8, [25] [26] [27] [28] [29] [30] [31] and prospective [7, [32] [33] [34] [35] cohort studies showed that the rates of VTE recurrence and major bleeding are particularly high in cancer patients with VTE receiving anticoagulant therapy (Tables S2 and S3 of Supporting Information). Prospective studies reported a 2 to 5-fold increase in the rate of VTE recurrence and a 2 to 6-fold increase in the rate of major bleeding in cancer patients compared with non-cancer patients (Table S3 of Supporting Information) [7, [32] [33] [34] [35] . In addition, VTE recurrence and bleeding rates appear to correlate with cancer stage [7] .
Initial treatment of established VTE
The definition of initial treatment corresponds to the first 10 days of anticoagulation.
Short-term unfractionated heparin (UFH) followed by vitamin K antagonists (VKA). The literature search failed to retrieve any randomized study evaluating the benefit-risk ratio of short-term UFH followed by VKA for VTE treatment in cancer patients. We identified six retrospective studies in cancer patients treated for VTE with UFH + VKA, showing high rates of recurrent VTE (11-38%) and major bleeding (8-35%) up to 10 months of follow-up (Table S2 of Supporting Information) [8, 25, 26, [28] [29] [30] . In the control arms of two randomized studies comparing short-term UFH + VKA with short-term low-molecular-weight heparins (LMWHs) + VKA or fondaparinux + VKA, the rates of VTE recurrence and major bleeding after 3 months of treatment were 10-17.2% and 6.3-7%, respectively, in the subgroups of cancer patients (Table S4 of Supporting Information) [36, 37] . In conclusion, the treatment of VTE in cancer patients with UFH followed by VKA is associated with a high rate of recurrence and bleeding.
Short-term LMWH followed by VKA. The literature search did not retrieve any randomized study or metaanalysis evaluating the benefit-risk ratio of short-term LMWH followed by VKA for VTE treatment in cancer patients. Five randomized studies were performed in patients with cancer and used short-term LMWH followed by VKA as one of the treatments compared (Table S4 of Supporting Information) [37] [38] [39] [40] [41] . In these studies, including a total of 628 cancer patients, the rate of recurrent VTE was 6.7-16.9% and that of major bleeding was 2.9-16% after 6 months follow-up.
In conclusion, the treatment of VTE in cancer patients with LMWH followed by VKA is associated with high rates of both relapse and bleeding.
Short-term LMWH vs. short-term UFH followed by VKA. Eight meta-analyses were identified that compared short-term LMWH with short-term UFH in the initial treatment of VTE, both drugs being then switched to VKA, in populations including patients with cancer (the proportion of these patients, when specified, ranging from 5% to 23%) (Table S5 of Supporting Information) [42] [43] [44] [45] [46] [47] [48] [49] . In the general population, LMWHs were more effective than (in three metaanalyses [42, 43, 47] ) or at least as effective as (in the five remaining meta-analyses) UFH. LMWHs were associated with a significantly lower risk of bleeding than UFH in five metaanalyses [42] [43] [44] [45] 47] , and significantly reduced overall mortality in the six meta-analyses in which death rates were reported [42] [43] [44] [45] [46] [47] .
In two meta-analyses specifically performed in cancer patients, the rates of recurrence did not differ statistically between LMWH and UFH [50, 51] ; the relative effect regarding bleeding was not reported. Interestingly, a beneficial effect of LMWH vs. UFH was observed on the risk of death [50, 51] : in the most recent meta-analysis in 801 cancer patients, the death rate was reduced from 18.9% with UFH to 13.1% with LMWH [relative risk (95% confidence interval), 0.71 (0.52-
Short-term fondaparinux vs. short-term LMWH or UFH followed by VKA. In post-hoc analyses of the subgroups of cancer patients in two randomized controlled trials comparing fondaparinux with LMWH for the treatment of DVT (n = 237) and with UFH for the treatment of PE (n = 240), the rate of VTE recurrence after 3 months was lower with fondaparinux than with UFH, but higher than with enoxaparin, with no difference between fondaparinux and the comparators in the risk of bleeding or death (Tables S5 and S6 of Supporting Information) [37, 51] . Thrombolytics. The use of thrombolytic drugs in cancer patients with VTE was evaluated in only one study retrieved, a retrospective multicenter cohort study comprising patients from five randomized studies (Table S7 of Supporting Information) [52] . In this study, 57 cancer patients with PE were treated first with tissue plasminogen activator or urokinase and then by intravenous UFH. The rate of recurrent VTE within 14 days after treatment administration was 6%, the rate of major bleeding within 72 h after treatment administration being 12%.
Vena cava filters. Data on the use of vena cava filters in cancer patients with VTE are scarce. Fourteen retrospective cohort studies including 29-308 patients [28, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] were identified (Table S8 of Supporting Information). Among these studies, 11 were non-comparative and three compared the efficacy of vena cava filters with that of heparin followed by VKA. Contraindication for anticoagulant treatment was the principal reason for vena cava filter placement. The heterogeneity of the results can probably be ascribed to differences in the type of recurrent VTE analyzed and concomitant treatment with an anticoagulant (when specified).
Recommendations. 
Early maintenance and long-term treatment of established VTE
The early maintenance treatment period corresponds to the time beyond the tenth day up to the third month of anticoagulation, long-term treatment of VTE corresponding to treatment indicated beyond the third month of anticoagulation (Table 3) .
Early maintenance treatment and long-term treatment by use of LMWH. We identified one prospective cohort study evaluating early maintenance treatment by LMWH [66] , and six randomized studies comparing the benefit-risk ratio of early maintenance and long-term treatment by LMWH with that of short-term heparin followed by VKA, four in patients with cancer [36, [38] [39] [40] and two in the general population including cancer patients [41, 67] (Table S9 of Supporting Information). In one of these randomized studies [36] , the heparin used in the control group was UFH, whereas it was an LMWH in the five remaining studies. Anticoagulant treatment lasted 3-6 months. Three of the randomized trials showed a significant benefit of extended LMWH treatment in terms of VTE recurrence [36, 39, 41] . In the five randomized trials for which the information was provided, the safety, in terms of bleeding risk, of extended LMWH treatment was at least as good as that of short-term heparin followed by VKA. The CANTHANOX study showed that LMWH was more effective than VKA in reducing the risk of the composite of major bleeding or recurrent VTE at 3 months (P = 0.04; logrank test) [38] . Five meta-analyses were performed on studies comparing extended LMWH treatment with short-term heparin followed by VKA, two concerning the general population [68, 69] , including cancer patients, and three specifically focusing on cancer patients [20, [70] [71] [72] (Table S10 of Supporting Information). All but one [68] concluded that early maintenance treatment (10 days to 3 months) and long-term treatment (beyond 3 months) by LMWH alone vs. heparin (UFH or LMWH) followed by VKA in cancer patients with VTE decreased the VTE recurrence rate by 50% [20, [69] [70] [71] [72] , with no increase in bleeding risk or any effect on the mortality rate [20, [70] [71] [72] . The remaining meta-analysis included seven studies totaling 1379 patients [68] , of which only one had enrolled cancer patients. In the overall population, the rates of clinical events (VTE recurrence, major bleeding or death) were comparable in the LMWH extended treatment group and the VKA group [68] .
In conclusion, in cancer patients with VTE, early maintenance treatment (10 days to 3 months) and long-term treatment (beyond 3 months) with LMWH significantly reduced the risk of VTE recurrence by approximately 50% vs. shortterm heparin followed by VKA, with no increase in bleeding risk, but did not decrease mortality.
Long-term use of idraparinux. One randomized trial (VANGOGH-DVT), not specific to cancer patients, compared the efficacy and safety of idraparinux with those of heparin (LMWH or UFH)+VKA administered for 3-6 months to patients with DVT (92% of patients received 6-month therapy) [73] (Table S11 of Supporting Information) . Post-hoc analysis of the subgroup of patients with active cancer (n = 421) showed that idraparinux was as effective as VKA, with the same rate of bleeding events.
Duration of anticoagulation. Only one specific study on the duration of anticoagulation was identified [74] (Table S12 of supporting information). In this study, 409 patients with active cancer and a first episode of DVT received LMWH for 6 months and were then divided into three groups on the basis of the results of a duplex ultrasound examination: patients with residual venous thrombosis were randomized to continuation (Group A1) or discontinuation of anticoagulation therapy (Group A2), and those without residual venous thrombosis were to discontinue anticoagulant therapy (Group B). Rates of VTE recurrence were 14.2%, 21.9% and 2.8% in Groups A1, A2 and B, respectively (A1 vs. B, P = 0.03; A2 vs. B, P = 0.01; A1 vs. A2, P = 0.73). Corresponding rates of major bleeding were 4.2%, 1.6% and 1.9%.
So far, no study has compared 3 vs. 6 months of LMWH. Four clinical trials investigating VTE treatment in cancer patients, although not specifically designed to evaluate the duration of anticoagulation, showed a benefit of early maintenance treatment (10 days to 3 months) and long-term treatment with LMWH alone (beyond 3 months) compared with short-term heparin followed by VKA [36, [38] [39] [40] (Table S9 of Supporting Information). Two of these studies used a 6-month LMWH regimen. 
Recommendations
Treatment of VTE recurrence in cancer patients under anticoagulation
We identified one retrospective cohort study specifically designed to evaluate the treatment of VTE recurrence in 70 cancer patients who experienced recurrence while receiving an anticoagulant [75] (Table S13 of Supporting Information). At the time of the recurrence, 67% of patients were receiving LMWH and 33% were receiving a VKA. VTE recurrence was treated with either dose escalation of LMWH in patients already receiving LMWH (increase of the weight-adjusted dose by 20-25% for at least 4 weeks or to the therapeutic range), or
International guidelines on thrombosis and cancer 61 initiation of LMWH treatment at a therapeutic dose in patients who were on VKA. All patients were followed-up for a minimum of 3 months after the index VTE recurrence. A total of six patients (8.6%) experienced a second recurrence of VTE during the follow-up period. Three patients (4.3%) had bleeding complications. The median time between the index VTE recurrence to death was 11.4 months (range, 0-83.9 months; death rate, 36/70). The authors concluded that cancer patients with recurrent VTE have a short median survival and that escalating the dose of LMWH can be effective for treating cases that are resistant to standard, weight-adjusted doses of LMWH or a VKA. In the 14 retrospective cohort studies of vena cava filters in cancer patients, a substantial proportion of patients received these filters to prevent VTE recurrence [28, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] (Table S8 of Supporting Information). However, no data are available regarding this subset of patients.
Recommendation. In the event of VTE recurrence, three options can be considered: (i) switch from VKA to LMWH in patients treated with VKA; (ii) increase in LMWH dose in patients treated with LMWH, and (iii) vena cava filter insertion [Best clinical practice, based on evidence of very low quality and an unknown balance between desirable and undesirable effects].
Values and preferences: individual decision.
New oral anticoagulant agents (NOAC)
The experts of the working group acknowledge the potential benefit of new oral anticoagulant agents for the treatment of VTE in cancer patients. However, the group considered it was premature to issue recommendations or guidance on the use of these new agents in this setting in view of the absence of specific data, and considering that none of these products had yet been approved for use for VTE treatment at the time this document was prepared and none of the experts had enough clinical experience with their use to give any meaningful Ôbest practice adviceÕ.
Prophylaxis of VTE in cancer patients
Prophylaxis of VTE in surgical cancer patients. LMWH or UFH compared with placebo or no treatment. Only one randomized controlled study in 99 Indian patients undergoing colorectal surgery for cancer, comparing LMWH for 6 days with no prophylaxis, has been published since January 1996 [76] (Table S13 of Supporting Information). No postoperative VTE occurred in either group and there was no difference in the rate of bleeding events between the two groups.
Three meta-analyses of older randomized studies were identified, one conducted in general surgery patients [77] , and two focusing on patients undergoing gynecologic surgery [78, 79] (Table S14 of Supporting Information). Overall, LMWH and UFH were superior to placebo or no prophylaxis in preventing postoperative VTE in cancer patients. In one meta-analysis [77] , the rate of any bleeding was higher with LMWH than with placebo or no treatment.
LMWH vs. UFH. Three randomized double-blind studies comparing LMWH with UFH for the prevention of VTE in surgical patients were identified, two conducted specifically in cancer patients [80, 81] and one in patients undergoing colorectal surgery (35.2% for cancer) [82] (Table S13 of Supporting Information). In these studies, LMWH and UFH showed similar efficacy with a trend towards less bleeding with LMWH.
In three meta-analyses [77, 79, 83] , including studies published before January 1996, UFH given three times a day was as effective as LMWH once a day, but LMWH once a day appeared to be superior to UFH twice a day (Table S14 of Supporting Information). The rate of bleeding was the same with UFH and LMWH. (Table 4) . Two randomized doubleblind trials compared two anticoagulant agents for VTE prophylaxis after abdominal surgery [84, 85] (Table S15 of Supporting Information).
Comparison of drugs
In the first study in 2927 high-risk patients undergoing abdominal surgery, once-daily subcutaneous fondaparinux 2.5 mg and dalteparin 5000 IU administered for 5-9 days had comparable benefit-to-risk ratios [84] . In the subgroup of patients undergoing surgery for cancer (n = 1941, i.e. twothirds of the study population), fondaparinux reduced by 38.6% (95% CI, 6.7-59.6) the risk of symptomatic VTE and asymptomatic DVT, with a trends towards an increase in bleeding risk; major bleeding was reported in 3.4% of patients with fondaparinux and in 2.5% with dalteparin (P = 0.355).
In the second study in 1296 patients undergoing elective resection of colorectal adenocarcinoma, the benefit-to-risk ratios of once-daily subcutaneous nadroparin 2850 anti-Xa IU and enoxaparin 4000 anti-Xa IU were compared [85] . Treatments were administered for 7-11 days. At day 12, the rate of symptomatic and asymptomatic VTE was 15.9% with nadroparin and 12.6% with enoxaparin (RR = 1.27; 95% CI, 0.93-1.74). Corresponding rates of symptomatic VTE were 0.2% vs. 1.4% (RR = 0.12; 95% CI, 0.01-0.92) at day 12 and 0.6% vs. 2.1% at day 60 (NS). Major bleeding occurred less frequently with nadroparin than with enoxaparin (7.3% vs. 11.5%, P = 0.012). (Table 4) . Only one double-blind trial has compared two doses of the same anticoagulant agent for VTE prophylaxis in a surgical context [86] (Table S15 of Supporting Information). Once daily subcutaneous dalteparin 2500 antiXa IU and dalteparin 5000 anti-Xa IU administered for 8 days were compared in 1375 patients undergoing major elective abdominal surgery, 70% of these patients undergoing this procedure for cancer. The high-dose dalteparin regimen was more effective than the low-dose dalteparin regimen (postoperative total VTE rate, 8.5% vs. 14.9%; P < 0.001), with no statistically significant difference in terms of bleeding complications (4.6% vs. 3.6%, respectively).
Dose of LMWH
Extended duration of prophylaxis. We identified four prospective randomized studies evaluating extended prophylaxis with LMWH, one specifically in cancer patients [87] and three in the general population including cancer patients [88] [89] [90] (Table S16 of Supporting Information), and one meta-analysis of extended LMWH prophylaxis in cancer patients [91] (Table S17 of Supporting Information). Although two of the randomized studies were negative (one was stopped before the calculated number of patients was achieved), two studies were positive and the meta-analysis showed a reduced risk of postoperative VTE after major laparotomy surgery in cancer patients, with a trend towards an increased bleeding risk in the extended prophylaxis group.
External compression devices (ECD).
Three randomized studies in patients undergoing surgery for gynecologic [92] or brain [93, 94] tumors (Table S18 of Supporting Information) and one meta-analysis of studies in mixed neurosurgical patients [95] (Table S19 of Supporting Information) were identified. Overall, ECD and LMWH appeared to be equally effective in preventing VTE in major abdominal or pelvic surgery for gynecologic malignancies. As regards prophylaxis after surgery for brain tumors, graduated compression stockings (GCS) + intermittent pneumatic compression (IPC) showed the same efficacy as GCS alone, and both ECD were superior to no prophylaxis; in neurosurgical patients, LMWH were superior to ECD despite an increase in minor bleeding, but with no increase in intracranial bleeding or in major bleeding.
Recommendations.
1 Use of LMWH once a day or a low dose of UFH three times a day is recommended to prevent postoperative VTE in cancer patients; pharmacological prophylaxis should be started 12-2 h preoperatively and continued for at least 7-10 days; there are no data allowing conclusions regarding the superiority of one type of LMWH over another 
Prophylaxis of VTE in medical cancer patients
Hospitalized cancer patients. No study evaluated the benefit-risk ratio of thromboprophylaxis specifically in hospitalized medical cancer patients. We therefore selected the randomized clinical trials comparing LMWH with UFH in hospitalized medical patients with reduced mobility [96] [97] [98] [99] included in the ACCP guidelines [12] , which previously addressed this question (Table S20 of Supporting Information). All but one of these [98] were double-blind studies. In addition, four randomized double-blind studies comparing LMWH with placebo in comparable patients were considered [100] [101] [102] [103] (Table S21 of Supporting Information). The percentage of cancer patients in the selected studies varied from 5% to 15%. These studies showed that LMWH and fondaparinux were superior to placebo in preventing VTE, with a non-significant trend towards an increased bleeding risk (except for enoxaparin 40 mg and fondaparinux). LMWH and UFH showed similar efficacy and safety. No study reported a difference in efficacy between cancer and non-cancer patients.
Children with acute lymphocytic leukemia (ALL) treated with L-asparaginase. Two small studies conducted in children with acute lymphocytic leukemia (ALL) treated with L-asparaginase were identified [104, 105] (Table S22 of Supporting Information). The first was a randomized study comparing antithrombin supplementation with no supplementation [105] . No differences were seen between the two groups in terms of either VTE events or bleeding complications. The second was a non-randomized prospective cohort study conducted during two periods, comparing antithrombin supplementation alone (1995) (1996) (1997) (1998) (1999) (2000) with antithrombin supplementation + LMWH (2001-2006) [104] . The rates of thromboembolic events were 12.7% and 0% (P = 0.02), respectively, with no reports of bleeding complications. Overall, the rate of symptomatic VTE in children with ALL was around 5%.
Ambulatory patients treated with chemotherapy. We identified two prospective randomized studies comparing LMWH with no treatment [106, 107] , three randomized double-blind trials comparing LMWH with placebo [108- International guidelines on thrombosis and cancer 63 110] and one analysis of pooled data from two randomized double-blind studies (PROTECH and TOPIC 2) comparing LMWH with placebo [111] (Table S23 of Supporting  Information) .
Overall, these studies showed that primary prophylaxis with LMWH in patients treated with chemotherapy non-significantly increased intracranial bleeding in patients with a brain tumor, decreased the rate of VTE without an excess of bleeding in patients with locally advanced or metastatic pancreatic cancers (at sub-therapeutic dosages) or locally advanced or metastatic lung cancers, but had no effect on VTE in patients with metastatic breast cancers. LMWH may increase the bleeding risk, particularly in the context of thrombocytopenia.
Patients treated with thalidomide or lenalidomide. We identified two retrospective studies of VTE prophylaxis in cancer patients treated with thalidomide [112, 113] , one prospective randomized study comparing aspirin, LMWH and warfarin in patients with myeloma [114] (Table S24 of Supporting Information) and two meta-analyses addressing the issue of anticoagulation in patients with myeloma [115, 116] (Table S25 of Supporting Information). None of the studies included a placebo group.
These studies and meta-analyses showed that the rate of VTE in patients treated with IMiDs (thalidomide and lenalidomide) combined with steroids and/or chemotherapy (doxorubicin) is very high. Prophylactic doses of LMWH, aspirin (100 mg day ) or warfarin to maintain INR within the therapeutic range reduced the risk of thromboembolic events in multiple myeloma patients treated with lenalidomide or thalidomide with no increase in bleeding risk. [55, 57, 117, 118] ; one was prospective and three were retrospective (Table S26 of supporting information). Overall, few patients were included in these studies (between 11 and 51) and their characteristics were heterogeneous. Anticoagulant treatment varied between studies: UFH + VKA, tinzaparin alone, or vena cava filter insertion. Under anticoagulation, the rates of VTE recurrence and bleeding events varied between 0% and 12% and 0% and 17.4% (intracerebral bleeding, 0-7%), respectively. In the two studies assessing the value of vena cava filters in a total of 52 patients, the rate of VTE recurrence was about 40% [55, 57] .
Recommendations
Prophylaxis of VTE in cancer patients undergoing neurosurgery. We identified eight prospective randomized studies [94, [119] [120] [121] [122] [123] [124] [125] , of which four were double-blind [122] [123] [124] [125] (Table S27 of Supporting Information). In these studies, the majority of patients underwent neurosurgery for a brain tumor. In addition, two meta-analyses of studies evaluating therapeutic measures to prevent VTE in a mixed neurosurgical population were available [95, 126] (Table S28 of Supporting  Information) . Overall, compared with placebo or no treatment, LMWH and UFH reduced the risk of postoperative VTE by 50% without an excess of major bleeding but with a 2-fold higher rate of minor bleeding. LMWH and UFH (5000 IUSC/ 12 h) were associated with the same rates of VTE and bleeding events. The reduction in VTE rate with ECD was about 60% compared with no prophylaxis, GCS + IPC having the same efficacy as GCS alone. LMWHs were shown to be superior to ECD, with a reduction in VTE rate from 40% to 20%, an increase in minor bleeding (RR: 2), and no increase in intracranial bleeding or major bleeding. After surgery for brain or spinal tumors, adding LMWH to an intermittent compression device increased the risk of minor bleeding but not that of major or intracranial bleeding.
Other special situations. For the treatment and prophylaxis of VTE in cancer patients with thrombocytopenia or renal insufficiency, or in pregnant women with cancer, the literature search retrieved no study. For thrombocytopenia or renal insufficiency, we used the thresholds generally constituting exclusion criteria in clinical trials as a basis for discussion to reach consensus. ), an ECD may be applied, and pharmacological prophylaxis may be considered on a caseby-case basis; in patients with severe renal failure (creatinine clearance < 30 mL min 
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